Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Naftidrofuryl for intermittent claudication.

T L M De Backer1, R Vander Stichele, P Lehert

  • 1Ghent University, Heymans Institute of Pharmacology, De Pintelaan 185, Gent, Belgium, B-9000. tine.debacker@ugent.be

The Cochrane Database of Systematic Reviews
|April 22, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Geographical variation of COVID-19 vaccination coverage, ethnic diversity and population composition in Flanders.

Vaccine: X·2022
Same author

A large observational data study supporting the PROsPeR score classification in poor ovarian responders according to live birth outcome.

Human reproduction (Oxford, England)·2021
Same author

Long-term outcome of patients undergoing in-vitro fertilisation in France: The outcome study.

Journal of gynecology obstetrics and human reproduction·2020
Same author

How to achieve the desired outcomes of advance care planning in nursing homes: a theory of change.

BMC geriatrics·2018
Same author

Systematic Quality Monitoring For Specialized Palliative Care Services: Development of a Minimal Set of Quality Indicators for Palliative Care Study (QPAC).

The American journal of hospice & palliative care·2016
Same author

Blood pressure in the Congolese adult population of South Kivu, Democratic Republic of Congo: Preliminary results from the Bukavu Observ Cohort Study.

Revue d'epidemiologie et de sante publique·2015
Same journal

Interventions to prevent or cease electronic cigarette use in children and adolescents.

The Cochrane database of systematic reviews·2026
Same journal

Drugs to improve anaemia, quality of life, and physical function in people with myelodysplastic syndromes (MDS).

The Cochrane database of systematic reviews·2026
Same journal

Interventions for smoking cessation in inpatient psychiatry settings.

The Cochrane database of systematic reviews·2026
Same journal

Mechanical thromboprophylaxis for preventing intradialytic hypotension in people undergoing maintenance haemodialysis.

The Cochrane database of systematic reviews·2026
Same journal

Prognostic models for predicting intensive care unit admission or mortality in critically ill adults not yet been admitted to the intensive care unit.

The Cochrane database of systematic reviews·2026
Same journal

Views and experiences of weight management for people living with mobility‑limiting conditions, intellectual disabilities or severe mental illness: a qualitative evidence synthesis.

The Cochrane database of systematic reviews·2026
See all related articles

Naftidrofuryl significantly improves walking distance for intermittent claudication patients. This meta-analysis of individual patient data confirms its efficacy, showing a meaningful benefit in pain-free walking distance.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology
  • Clinical Trials

Background:

  • Intermittent claudication (IC) management primarily relies on lifestyle changes and cardiovascular prevention.
  • The efficacy of vasoactive agents, like naftidrofuryl, for symptomatic IC treatment remains debated.

Purpose of the Study:

  • To assess the efficacy and safety of oral naftidrofuryl versus placebo in improving pain-free walking distance (PFWD) in IC patients.
  • This evaluation utilized a meta-analysis of individual patient data (IPD).

Main Methods:

  • A systematic search identified randomized controlled trials (RCTs) with low to moderate risk of bias and available IPD.
  • Data from 1083 patients across seven RCTs were analyzed using multilevel and random-effect models.
  • Therapeutic success was defined as at least a 50% improvement in walking distance.

Related Experiment Videos

Main Results:

  • Naftidrofuryl demonstrated a statistically significant improvement in PFWD compared to placebo (ratio of relative improvement: 1.37).
  • The absolute difference in responder rates was 22.3%, with a number needed to treat of 4.5.
  • These findings indicate a clinically meaningful benefit for patients with IC.

Conclusions:

  • Oral naftidrofuryl provides a statistically significant and clinically meaningful improvement in walking distance for individuals with intermittent claudication.
  • Enhanced data accessibility for IPD meta-analyses from pharmacological trials is recommended.
  • Periodic reassessment of risk-benefit profiles for established pharmaceutical products is crucial.